SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - June 01, 2012) -
NicOx Board decides not to exercise its option to acquire the remaining
June 1, 2012. Sophia Antipolis, France. www.nicox.com
NicOx S.A. (NYSE Euronext Paris: COX) today announces that its
directors has unanimously decided at its May 31, 2012 meeting not to
NicOx's option to acquire the remaining 88.2% of equity of Altacor.
acquired 11.8% of the equity of Altacor in March 2012. Accordingly, the
to acquire the remaining shares of Altacor lapsed on May 31, 2012.
NicOx's Board deemed that it was not in the best interest of NicOx
shareholders to acquire the remaining 88.2% of equity of Altacor at this
NicOx will retain a stake of 11.8% in Altacor and Gavin Spencer, Executive
President, Corporate Development of NicOx will continue to be a
Altacor's Board of Directors.
NicOx remains fully committed to its strategy of building a
international Ophthalmology Company focused on therapeutics,
Michele Garufi, Chairman and Chief Executive Officer of NicOx, commented:
key shareholder, we remain interested in Altacor and we will continue to
their evolution with interest. At the same time, we are very
pursuing our negotiations to in-licence or acquire businesses and products
will enable us to build a commercial presence in the main European
in the US. We will update the market as soon as any of the ongoing
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is building an international
late-stage development and commercial Ophthalmology Company
therapeutics, diagnostics and devices. As of March 2012, NicOx holds an
stake in the UK-based ophthalmology company Altacor.
NicOx is also developing an internal portfolio of New Molecular Entities
through the application of its proprietary nitric oxide-donating R&D
The Company's pipeline includes several nitric oxide-donating NMEs
potential treatment of ophthalmological, inflammatory and
diseases, which are in development internally and with partners, who
Bausch + Lomb, Merck (known as MSD outside the United States and
NicOx S.A. is headquartered in France and is listed on Euronext
(Compartment C: Small Caps).
This press release contains certain forward-looking statements.
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
presented in the 4th chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2011 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 29, 2012 and available on NicOx's
(www.nicox.com) and on the AMF's website (www.amf-france.org).
FTI Consulting London
Jonathan Birt · D+44 (0)20 7269 7205 · M +44 (0) 7515 597 858
Stephanie Cuthbert · D +44 (0)20 3077 0458 · M +44 (0)
FTI Consulting Paris
Guillaume Granier · D +33 1 47 03 68 61 · M + 33 6 32 65 79 28
Stephanie Bia · D + 33 (0) 1 47 03 68 16 · M +
6 79 44 66 55
Les Taissounières - Bât HB4 - 1681 route des Dolines - BP313 -
Antipolis Cedex - France
Tel: +33 (0)4 97 24 53 00 · Fax: +33 (0)4 97 24 53 99
NicOx Board decides not to exercise its option to acquire the remainin:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE